Ann Dermatol.  2018 Jun;30(3):394-396. 10.5021/ad.2018.30.3.394.

Isoginkgetin Inhibits Insulin-Like Growth Factor-1-Induced Sebum Production in Cultured Human Sebocytes

Affiliations
  • 1Department of Dermatology, Chungnam National University School of Medicine, Daejeon, Korea. cdkimd@cnu.ac.kr
  • 2GF-Herb Co., Nonsan, Korea.
  • 3Picostech Co., Pyeongtaek, Korea.
  • 4Skin Med Co., Daejeon, Korea.

Abstract

No abstract available.


MeSH Terms

Humans*
Sebum*

Figure

  • Fig. 1 (A) Structure of isoginkgetin. (B) Cytotoxicity of isoginkgetin. Sebocytes were treated with isoginkgetin at the indicated concentrations for 2 days. Cell viability was measured by MTT assay. The mean values±standard deviation are averages of triplicate measurements. (C) Effect of isoginkgetin on lipogenesis in sebocytes. Cells were treated with insulin-like growth factor-1 (IGF-1) and isoginkgetin at the indicated concentrations for 2 days. Effect of isoginkgetin on IGF-1-induced lipid production was determined by thin layer chromatography. Production of squalene and wax ester was significantly inhibited by isoginkgetin.

  • Fig. 2 (A) Effect of isoginkgetin on intracellular signaling. Sebocytes were pretreated with isoginkgetin at the indicated concentrations for 30 minutes, then insulin-like growth factor-1 (IGF-1) was added to the culture and incubated for a further 30 minutes. Cellular proteins were prepared and phosphorylation of signaling molecules was evaluated by Western blot. (B) Effect of isoginkgetin on the protein level for lipogenic transcription factors. Cells were treated with IGF-1 and isoginkgetin at the indicated concentrations for 2 days. Protein level for sterol response element-binding protein-1 (SREBP)-1 and peroxisome proliferator-activated receptor-γ (PPAR-γ) was evaluated by Western blot. Actin was used as a loading control.


Reference

1. Shi VY, Leo M, Hassoun L, Chahal DS, Maibach HI, Sivamani RK. Role of sebaceous glands in inflammatory dermatoses. J Am Acad Dermatol. 2015; 73:856–863. PMID: 26386632.
Article
2. Chen W, Obermayer-Pietsch B, Hong JB, Melnik BC, Yamasaki O, Dessinioti C, et al. Acne-associated syndromes: models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol. 2011; 25:637–646. PMID: 21198949.
Article
3. Kim H, Moon SY, Sohn MY, Lee WJ. Insulin-like growth factor-1 increases the expression of inflammatory biomarkers and sebum production in cultured sebocytes. Ann Dermatol. 2017; 29:20–25. PMID: 28223742.
Article
4. Krautheim A, Gollnick HP. Acne: topical treatment. Clin Dermatol. 2004; 22:398–407. PMID: 15556726.
Article
5. Hwang YL, Im M, Lee MH, Roh SS, Choi BW, Kim SJ, et al. Inhibitory effect of imperatorin on insulin-like growth factor-1-induced sebum production in human sebocytes cultured in vitro. Life Sci. 2016; 144:49–53. PMID: 26631504.
Article
6. Smith TM, Gilliland K, Clawson GA, Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol. 2008; 128:1286–1293. PMID: 17989724.
Article
7. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, et al. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol. 2006; 126:2002–2009. PMID: 16675962.
Article
8. Lee SJ, Choi JH, Son KH, Chang HW, Kang SS, Kim HP. Suppression of mouse lymphocyte proliferation in vitro by naturally-occurring biflavonoids. Life Sci. 1995; 57:551–558. PMID: 7623623.
Article
9. O'Brien K, Matlin AJ, Lowell AM, Moore MJ. The biflavonoid isoginkgetin is a general inhibitor of Pre-mRNA splicing. J Biol Chem. 2008; 283:33147–33154. PMID: 18826947.
10. Yoon SO, Shin S, Lee HJ, Chun HK, Chung AS. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol Cancer Ther. 2006; 5:2666–2675. PMID: 17121913.
Article
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr